As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: January 2, 2012
by Elizabeth Landau for CNN:
Scientists are finding more clues to help determine whether people with mild dementia symptoms are at risk for Alzheimer’s.
A new study suggests that biomarkers found in cerebrospinal fluid (fluid that surrounds the spinal cord and brain and acts as a protective cushion) could predict who would develop Alzheimer’s disease 90% of the time among patients with mild cognitive impairment, a condition characterized by measurable memory problems.
Researchers report these findings in the journal Archives of General Psychiatry.
This is the longest clinical follow-up ever of patients who begin with mild cognitive impairment, researchers reported. Patients were tracked from four to 12 years, with a median of 9.2 years. The research builds on a 2006 Lancet Neurology study that followed patients for a median of 5.2 years, beginning with a group of 137 volunteers with mild cognitive impairment.The new study is important because of the long follow-up period, according to Adam Brickman, assistant professor of neuropsychology at Columbia University School of Medicine, who was not involved in the research.
Knowing which patient with mild cognitive impairment patients may go on to develop Alzheimer’s is vital information for researchers, who are looking for treatments for the fatal brain disease. The current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said. Clinical trials can better focus their efforts if patients are known to be in the early stages of Alzheimer’s. Generally, about 30% to 60% of patients with mild cognitive impairment show evidence of underlying symptoms of Alzheimer’s, so not everyone with this condition is a good candidate for an Alzheimer’s trial.
Researchers focused on two biomarkers previously thought to be involved in Alzheimer’s disease: a kind of protein called beta-amyloid, and another protein type called tau. Experts believe a decrease in beta-amyloid in the fluid of the spinal cord is associated with a toxic buildup of that protein in the brain, which causes the formation of plaques linked to Alzheimer’s disease. Tau has been tied to neurofibrillary tangles in the brain; researchers find that an increase in tau in cerebrospinal fluid is associated with Alzheimer’s also.
The results from the study suggest that beta-amyloid is a much earlier predictor of Alzheimer’s disease than tau, which supports the hypothesis that beta-amyloid accumulation in the brain occurs first in the course of the disease.
Some of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer’s disease during the longer follow-up. That suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer’s disease, researchers say.
The association between biomarkers in the fluid and Alzheimer’s was also described in studies in December 2009 and August 2010, building on the idea that a spinal tap could be useful in predicting Alzheimer’s.
When these sorts of studies get published, Brickman and other doctors get phone calls from aging adults wondering whether they should be getting spinal taps to assess their risk. But it’s too early to use this as a diagnostic tool in clinical settings, says Brickman. Down the road, the “fantasy” is that asymptomatic people will be able to get a biomarker test to determine whether they’ll one day get Alzheimer’s, but that’s not possible right now, he adds.
“What I tell people is: If they’re worried about their thinking abilities, that they should make an appointment with a neuropsychology or a neurologist to get an evaluation,” Brinkman says. “The way we diagnose Alzheimer’s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.”
As scientists gain more insight into predicting Alzheimer’s, aging adults may struggle with the question of whether they want to know their risk, especially since there’s still no cure. Some people want to enroll in clinical trials as soon as they start showing symptoms; others would rather be ignorant of their status since there is no cure. In looking for treatments, however, researchers depend on people’s willingness to contribute to science.
The Alzheimer’s Association runs a system called TrialMatch. Check it out if you’re interested in finding a trial for yourself or someone you care about.
It is a devastating omission that may have undercut years of work by brilliant researchers from around the world. Millions of dollars and countless hours have been spent investigating dementia. But in the view of...
A stroll through the Dutch community of De Hogeweyk is a journey to what could be the future of dementia care. Located within the small town of Weesp, just outside of Amsterdam, De Hogeweyk is...
Intimate-partner violence (IPV) is a pattern of physical and/or sexual violence inflicted by an intimate or ex-intimate partner. Global estimates published by the World Health Organization indicate that about 1 in 3 women have experienced...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.